ScripUnity Biotechnology, a biotech firm developing drugs that eliminate or modulate senescent cells to treat diseases of aging, has been making the case for its approach in retinal diseases for the last f
ScripThe pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner
ScripWindtree Therapeutics, Inc. hopes eventually to bring its first-in-class SERCA 2a activator istaroxime to market for treatment of acute heart failure, but along the way to getting potentially approva